Coegin Pharma AB (NGM:COEGIN)
Sweden flag Sweden · Delayed Price · Currency is SEK
3.200
+0.130 (4.23%)
At close: Jun 27, 2025

Coegin Pharma AB Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cost of Revenue
0.010.020.02---
Gross Profit
-0.01-0.02-0.02---
Selling, General & Admin
19.8320.2925.2134.9431.9148.6
Other Operating Expenses
-0.030.01-0.43-2.97-4.74-2.34
Operating Expenses
22.8223.3227.834.6927.1846.28
Operating Income
-22.84-23.33-27.82-34.69-27.18-46.28
Interest Expense
-0.01-0.46-0.05-0.22--
Interest & Investment Income
0.0100.020.01-0.04
Earnings From Equity Investments
-0.05-0.05----
Currency Exchange Gain (Loss)
0.060.06-0.14-0.330.04-0.01
Pretax Income
-22.83-23.78-27.98-35.24-27.15-46.24
Net Income
-22.83-23.78-27.98-35.24-27.15-46.24
Net Income to Common
-22.83-23.78-27.98-35.24-27.15-46.24
Shares Outstanding (Basic)
22199761
Shares Outstanding (Diluted)
22199761
Shares Change (YoY)
131.32%105.53%34.42%15.36%354.98%-
EPS (Basic)
-1.02-1.26-3.04-5.14-4.59-35.39
EPS (Diluted)
-1.03-1.26-3.04-5.14-4.59-35.39
EBITDA
-19.82-20.32-24.79-31.97-27.17-46.25
D&A For EBITDA
3.023.023.022.720.010.02
EBIT
-22.84-23.33-27.82-34.69-27.18-46.28
Revenue as Reported
0.070.060.573.134.762.34
Updated Jan 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.